Sector
PharmaceuticalsOpen
₹1,435Prev. Close
₹1,439.5Turnover(Lac.)
₹24,969.88Day's High
₹1,439.3Day's Low
₹1,406.1552 Week's High
₹1,702.0552 Week's Low
₹1,317.25Book Value
₹391.85Face Value
₹2Mkt Cap (₹ Cr.)
1,14,725.61P/E
24.95EPS
57.63Divi. Yield
0.9For the first nine months of FY25, Cipla's EBITDA margin stood at 26.9%, already above its full-year guidance of 24.5% to 25.5%.
Cipla reported a net profit of ₹1,303 crore, marking a 15% increase compared to the same period last year.
The VAI designation now clears the way for significant specialised launches, such as the Abraxane generic.
The company is now able to pursue important speciality medicine launches because to its VAI classification.
Here are some of the stocks that may see significant price movement today: Larsen & Toubro, Tata Power, Biocon, etc.
Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 161.47 | 161.43 | 161.36 | 161.29 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 27,812.45 | 24,476.66 | 22,352.19 | 19,766.27 |
Net Worth | 27,973.92 | 24,638.09 | 22,513.55 | 19,927.56 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Revenue | 13,091.79 | 11,302.71 | 12,659.15 | 11,389.9 |
yoy growth (%) | 15.82 | -10.71 | 11.14 | 5.77 |
Raw materials | -5,090.24 | -4,103.61 | -4,319.21 | -4,155.49 |
As % of sales | 38.88 | 36.3 | 34.11 | 36.48 |
Employee costs | -1,729.16 | -1,703.58 | -1,911.08 | -1,785.94 |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Profit before tax | 3,546.23 | 2,784 | 2,964.31 | 1,988.92 |
Depreciation | -460.01 | -468.62 | -599.78 | -529.61 |
Tax paid | -856.84 | -739.35 | -646.14 | -442.88 |
Working capital | 1,126.76 | -61.34 | 1,238.17 | 865.57 |
Other operating items |
Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 15.82 | -10.71 | 11.14 | 5.77 |
Op profit growth | 9.74 | 13.3 | 23.3 | 37.54 |
EBIT growth | 26.3 | -5.7 | 49.95 | 63.18 |
Net profit growth | 19.83 | 6.47 | 57.85 | 50.62 |
Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
---|---|---|---|---|---|
Gross Sales | 25,446.63 | 22,473.18 | 21,623.36 | 18,988.52 | 16,694.85 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 25,446.63 | 22,473.18 | 21,623.36 | 18,988.52 | 16,694.85 |
Other Operating Income | 327.46 | 279.94 | 139.98 | 171.07 | 437.14 |
Other Income | 746.57 | 475.45 | 280.91 | 265.99 | 344.2 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,742.2 | 151.67 | 4,18,132.11 | 1,181.05 | 0.77 | 5,985.33 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 5,618.55 | 81.25 | 1,49,254.4 | 518 | 0.53 | 2,302 | 513.62 |
Cipla Ltd CIPLA | 1,439.5 | 24.95 | 1,16,122.78 | 1,438.15 | 0.9 | 4,134.87 | 360.73 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,207.7 | 59.46 | 1,08,471.97 | 485 | 0.87 | 2,330 | 222.38 |
Mankind Pharma Ltd MANKIND | 2,481.6 | 52.93 | 1,02,347.53 | 416.38 | 0 | 2,396.57 | 334.18 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman (Non-Executive)
Y K Hamied
Vice Chairman
M K Hamied
Non-Exec. & Independent Dir.
Adil Zainulbhai
Managing Director & Global CEO
Umang Vohra
Company Sec. & Compli. Officer
Rajendra Chopra
Independent Director
Robert A Stewart
Independent Director
P R Ramesh
Independent Director
Mandar Purushottam Vaidya
Non Executive Director
Samina Hamied
Additional Director
Abhijit A Joshi
Non Executive Director
Kamil Hamied
Independent Director
Sharmila Paranjpe
Independent Director
Maya Hari
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Cipla Ltd
Summary
Cipla Ltd is one of the leading pharmaceutical companies in India. The Company is in the business of manufacturing, developing, and marketing wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs). Ciplas product portfolio spans complex generics as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective, CNS, and various other key therapeutic segments. With a rich portfolio, it is deepening presence in the home markets of India, as well as South Africa, North America, and other key regulated and emerging markets. Its 47 manufacturing sites around the world produce more than 50 dosage forms and over 1,500 products across wide range of therapeutic categories. Cipla Ltd was incorporated in the year 1935 with the name Chemical, Industrial & Pharmaceutical Laboratories Ltd. Khwaja Abdul Hamied, the founder of Cipla gave the company all his patent and proprietary formulas for several drugs and medicines, without charging any royalty. On August 17, 1935, Cipla was registered as a public limited company with an authorized capital of Rs 6 lakh. From its first manufacturing unit at Bombay Central in 1936, Cipla now has over 40 state-of-the art manufacturing facilities across the globe including India, USA, China and South Africa.In the year 1941, as the Second World War cuts off drug supplies, the company starts producing fine chemicals, dedicating all its facilities for the war effort. In the year 1952, the company se
Read More
The Cipla Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹1420.55 today.
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Cipla Ltd is ₹114725.61 Cr. as of 03 Feb ‘25
The PE and PB ratios of Cipla Ltd is 24.95 and 3.99 as of 03 Feb ‘25
The 52-week high/low is the highest and lowest price at which a Cipla Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Cipla Ltd is ₹1317.25 and ₹1702.05 as of 03 Feb ‘25
Cipla Ltd's CAGR for 5 Years at 26.51%, 3 Years at 15.00%, 1 Year at 3.74%, 6 Month at -6.90%, 3 Month at -7.70% and 1 Month at -5.86%.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.